Arca
Skip to content
Tools
Tools

Fibroblast growth factor receptor

Family in Homo sapiens that 14 drugs act on.

  • Drugs that act on it: 14
  • Approved: 4
  • In phases 1 to 3: 10
  • Sponsors: 11
  • Genes: 4

Who is on it, and how far along

Every drug ChEMBL records acting on FGFR1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 13
  • Other 1

Approved4

  • Nintedanib
  • Erdafitinib
  • Futibatinib
  • Infigratinib

Phase 33

  • Brivanib
  • Brivanib alaninate
  • Orantinib

Phase 25

  • Derazantinib
  • Fexagratinib
  • Rogaratinib
  • ENMD-981693
  • XL-999

Phase 12

  • CP-459632
  • LY-2874455

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

The landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Fibroblast growth factor receptor inhibitor.
NintedanibApprovedCSPC Pharmaceutical GroupSmall moleculeInhibitor26
ErdafitinibApprovedJohnson & JohnsonSmall moleculeInhibitor19
FutibatinibApprovedTaiho OncologySmall moleculeInhibitor14
InfigratinibApprovedHelsinn HealthcareSmall moleculeInhibitor5
BrivanibPhase 3Bristol-Myers SquibbSmall moleculeInhibitor0
Brivanib alaninatePhase 3Bristol-Myers SquibbSmall moleculeInhibitor0
OrantinibPhase 3Taiho Pharmaceutical Co., Ltd.Small moleculeInhibitor0
DerazantinibPhase 2Basilea PharmaceuticaSmall moleculeInhibitor1
FexagratinibPhase 2AstraZeneca PharmaceuticalsSmall moleculeInhibitor1
RogaratinibPhase 2BayerSmall moleculeInhibitor1
ENMD-981693Phase 2CASI PharmaceuticalsSmall moleculeInhibitor0
XL-999Phase 2Symphony Evolution, Inc.Small moleculeInhibitor0
CP-459632Phase 1—OtherInhibitor0
LY-2874455Phase 1—Small moleculeInhibitor0

Open trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 32 in all, from ClinicalTrials.gov.
Yangyin Qingfei Decoction for Radiation Pneumonitis PreventionNintedanibPhase 2Not yet recruitingThe First Affiliated Hospital of Zhejiang Chinese Medical UniversityNov 17, 2026
A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary FibrosisNintedanibPhase 2Not yet recruitingCSPC-NBP Pharmaceutical Co., Ltd.Nov 12, 2026
Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract CancerFutibatinibPhase 3Not yet recruitingUNICANCERAug 4, 2026
Antifibrotic Therapy Decision-Making in Pulmonary FibrosisNintedanib—Not yet recruitingBristol-Myers SquibbJul 23, 2026
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract CancerFutibatinibPhase 3RecruitingTaiho Pharmaceutical Co., Ltd.Jul 17, 2026
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary FibrosisNintedanibPhase 2RecruitingMannkind CorporationJul 1, 2026
Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC TrialFutibatinibPhase 2Not yet recruitingNorthwestern UniversityJun 10, 2026
A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary HypertensionNintedanib—Not yet recruitingCosmos Rx, IncMay 29, 2026
Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaFutibatinibPhase 1RecruitingNorthwestern UniversityMay 18, 2026
Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)NintedanibPhase 2Not yet recruitingFirst Affiliated Hospital of Wenzhou Medical UniversityMay 13, 2026
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary FibrosisNintedanibPhase 3Not yet recruitingHaisco Pharmaceutical Group Co., Ltd.Apr 9, 2026
Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILDNintedanib—RecruitingUniversity of PatrasMar 24, 2026
Open-Label, Long-Term, Extension Study of Infigratinib in Children With HypochondroplasiaInfigratinibPhase 2Enrolling by invitationQED Therapeutics, a BridgeBio companyFeb 6, 2026
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)InfigratinibPhase 2RecruitingQED Therapeutics, a BridgeBio companySep 11, 2025
Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia(AOBA Study)InfigratinibPhase 3Active, not recruitingKyowa Kirin Co., Ltd.Apr 13, 2025
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder CancerErdafitinibPhase 3RecruitingJanssen Research & Development, LLCApr 9, 2025
An Interventional Study of Infigratinib in Children With HypochondroplasiaInfigratinibPhase 2 / Phase 3Enrolling by invitationQED Therapeutics, a BridgeBio companyMar 12, 2025
Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor EntitiesFutibatinibPhase 2RecruitingInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestDec 9, 2024
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSErdafitinibPhase 2Not yet recruitingPeking University Shenzhen HospitalNov 18, 2024
Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene AlterationsErdafitinibPhase 2RecruitingSpanish Oncology Genito-Urinary GroupJul 22, 2024
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.FutibatinibPhase 2 / Phase 3Active, not recruitingTaiho Oncology, Inc.Jul 18, 2024
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)ErdafitinibPhase 2Active, not recruitingNational Cancer Institute (NCI)Apr 8, 2024
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder CancerErdafitinibPhase 3RecruitingJanssen Research & Development, LLCMar 20, 2024
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)ErdafitinibPhase 2Active, not recruitingNational Cancer Institute (NCI)Mar 13, 2024
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based TherapyFutibatinibPhase 2RecruitingYuanquan YangFeb 16, 2024
Drug Screening Using IMD in Bladder CancerErdafitinibEarly phase 1Enrolling by invitationBrigham and Women's HospitalJan 12, 2024
A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue TestingErdafitinib—Active, not recruitingBernie EiglNov 13, 2023
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsFutibatinibPhase 2Active, not recruitingTaiho Oncology, Inc.Jul 14, 2023
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/RearrangementsDerazantinibPhase 2Active, not recruitingInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestJan 3, 2022
Extension Study of Infigratinib in Children With Achondroplasia (ACH)InfigratinibPhase 2Enrolling by invitationQED Therapeutics, a BridgeBio companyDec 6, 2021
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)RogaratinibPhase 2Active, not recruitingNational Cancer Institute (NCI)Oct 22, 2020
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)FexagratinibPhase 2Active, not recruitingNational Cancer Institute (NCI)Jun 8, 2015

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2095217, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.